Trial Profile
Efficacy and Safety of Paricalcitol in the Reduction of Secondary Hyperparathyroidism After Renal Transplantation.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Paricalcitol (Primary) ; Calcifediol
- Indications Secondary hyperparathyroidism
- Focus Therapeutic Use
- Acronyms PARIDOINAL2013
- 17 Oct 2015 Status changed from active, no longer recruiting to completed as reported by European Clinical Trials Database record.
- 25 Sep 2015 Planned end date changed from 1 Sep 2015 to 1 Dec 2015, as reported by ClinicalTrials.gov.
- 25 Sep 2015 Planned primary completion date changed from 1 Jun 2015 to 1 Sep 2015, as reported by ClinicalTrials.gov.